Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dividend Distribution
confidence 92%
filed 2026-08-24
Item 8.01
News Corporation discloses ongoing execution of its authorized $1 billion share repurchase program, with daily buy-back notifications to the ASX showing purchases of approximately $286.4 million in Class A and Class B common stock as of August 24, 2026. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses share-repurchase programs. The filing explicitly states the repurchase is "to enhance shareholder value" and reports cumulative purchases of approximately $438.75 million of the $1 billion authorization to date.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-08-24
Item 8.01
News Corp disclosed daily buy-back notifications under its $1 billion repurchase program authorized July 15, 2025, reporting purchases of approximately 11.2 million Class A shares and 54,641 Class B shares on August 24, 2026, with total consideration of ~$288.1 million. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as they represent a return of capital, though the mechanism differs from traditional dividends.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-24
Item 3.01
NYSE Regulation has issued a formal Notice of unsuitability for continued listing under Sections 1001, 1002(e), 1003, and 1007 of the NYSE American Company Guide and has commenced delisting proceedings. The Company's Common Stock has been suspended from trading effective immediately and is expected to transfer to OTC Markets quotation. This is a textbook delisting event under Item 3.01, materially affecting liquidity, investor base, and the Company's ability to raise capital.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-24
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from e.l.f. Beauty's August 20, 2026 annual meeting. The filing presents certified voting tallies for four proposals: election of Class I directors (four nominees), advisory vote on executive compensation, advisory vote on compensation frequency, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material governance disclosure that informs investors of shareholder actions.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-24
Item 8.01
Zillow announced a resolution with the Federal Trade Commission and five state attorneys general regarding its multifamily rental listings syndication agreement with Redfin. The settlement, documented as a stipulated final order for equitable relief filed in federal court, allows the partnership to continue through 2030 while adding new standalone product offerings in 2027, removing legal uncertainty and affecting Zillow's rental marketplace strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 8.01
Precision Biosciences announced the first patient dosed in the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. This represents a material clinical development milestone marking the transition from preclinical work to human dosing in the company's lead program.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 7.01
PMI announced entry into a contract manufacturing arrangement with Philip Morris USA (Altria subsidiary) for combustible cigarettes, with first shipments expected in early 2027. This is a material operational/strategic partnership involving manufacturing collaboration between two major tobacco companies, but does not fit the specific categories of M&A activity, debt issuance, or other defined event types. The arrangement represents a significant business development that would affect investor assessment of PMI's operational strategy and revenue streams.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 8.01
Strive announced a bitcoin purchase of 1,110 BTC at ~$73,409 per coin during August 17-21, 2026, along with updated holdings of cash, bitcoin, and equity securities. This represents a material operational/treasury management activity consistent with the company's stated Bitcoin treasury strategy. While the disclosure is primarily informational (holdings updates), the scale of the bitcoin acquisition (~$81.5M notional value) and the company's strategic focus on digital assets make this material to investors assessing the registrant's capital allocation and treasury strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-24
Item 5.02
Dr. Martin D. Madaus was appointed as Interim President and CEO on August 22, 2026, following the resignation of John P. Marotta. Madaus brings significant industry experience as a former CEO of Millipore, Ortho Clinical Diagnostics, and Roche Diagnostics North America.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-08-24
Item 1.01
Skye Bioscience entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. on August 21, 2026, to sell up to $22,000,000 of ELOC Shares (common and non-voting convertible shares) plus a warrant to purchase additional shares valued at $5,000,000, pursuant to Section 4(a)(2) exemption. The transaction includes a 19.99% cap on outstanding shares (subject to stockholder approval for excess) and a 9.99% beneficial ownership limitation for the investor, representing significant equity dilution for existing shareholders.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 95%
filed 2026-08-24
Item 8.01
The disclosure describes unauthorized access to and exfiltration of data from Nutex Health's computer network, including patient, employee, and confidential business information. The company engaged third-party cybersecurity experts, activated response plans, and notified law enforcement. Although the company states it does not currently believe the incident has had material impact on operations or financial reporting, the data breach itself—involving potential exposure of sensitive healthcare information—constitutes a material cybersecurity incident requiring 8-K disclosure under Item 1.05 (or Item 8.01 as filed here).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-24
Item 1.01
Valvoline closed a $600 million offering of 6.125% senior notes due 2034 and amended its credit agreement to increase the revolving credit facility from $475 million to $600 million and extend its maturity, representing material debt issuance and credit facility modifications.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-24
Item 7.01
This Item 7.01 disclosure furnishes a shareholder letter addressing valuation methodology updates and mid-year financial outlook. The letter announces a shift from a discount-rate-based valuation approach to a "Historical Return Method" effective Q2 2026, discusses realized gains trends, capital deployment records ($362 million year-to-date), and revenue/earnings performance (30% YoY revenue growth, adjusted net income of $27.1M). While the filing disclaims materiality under Item 7.01 safe harbor, the substantive content—a material change in valuation methodology and strong financial performance disclosure—would affect a reasonable investor's assessment of the company's financial position and accounting practices, warranting classification as a material financial event outside the specific categories of earnings release, debt issuance, or impairment.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-24
Item 7.01
Ellington Financial announced its estimated book value per share of $13.63 as of July 31, 2026, along with a monthly dividend of $0.13 per share. This is a financial disclosure of net asset value and dividend information material to shareholders of a mortgage REIT, but does not fit the specific categories of earnings_release (no full quarterly/annual results), dividend_distribution (the dividend was previously announced), or other named financial event types. The disclosure is clearly financial in nature and material to investors assessing the company's value.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-24
Item 3.01
Nasdaq notified Fathom Holdings on August 21, 2026, that the company's stock bid price had closed below the $1.00 minimum for 30 consecutive business days, triggering a notice of non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until February 17, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public listing status.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-24
GSK announced that the US FDA has accepted for priority review a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) for locally advanced rectal cancer, with a PDUFA action date of February 2027. The announcement discloses positive interim data from the AZUR-1 trial showing sustained clinical complete responses and the potential for dostarlimab to eliminate the need for chemotherapy, radiation, and surgery for some patients. This is a material regulatory milestone and product development event that would affect a reasonable investor's assessment of GSK's pipeline and commercial prospects, but it does not fit neatly into the specific event categories (it is not an earnings release, M&A activity, executive change, or other named event type); accordingly, it is classified as an operational/strategic business milestone.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-24
GSK announced the first global regulatory approval of Hibsago (bepirovirsen) in Japan for chronic hepatitis B, representing a significant operational and commercial milestone. The approval is for an innovative functional cure treatment with demonstrated clinical efficacy (19% functional cure rate vs. 1% for standard care), supported by Phase III trial data. This is a material product approval event that would affect investor assessment of GSK's pipeline and commercial prospects, though it does not fit the discrete event categories of M&A, earnings, or executive changes.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-24
EX-99.1
This press release announces the commencement of Factory Acceptance Testing (FAT) for Electrovaya's automated lithium-ion cell assembly and formation equipment at its Jamestown, New York manufacturing facility. The disclosure describes a material operational milestone—the validation and commissioning phase of production equipment expected to complete by early October 2026, with subsequent installation and site acceptance activities. This represents a significant step toward the company's planned gigafactory becoming operational and would materially affect investor assessment of the company's progress toward commercial production capacity.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-08-24
HSBC Holdings plc has published a drawdown prospectus dated 24 August 2026 for the issuance of CNY2,500,000,000 in 1.950% Fixed Rate Notes due 2030 and CNY1,500,000,000 in 2.300% Fixed Rate Notes due 2034 under its Debt Issuance Programme. This constitutes creation of new direct financial obligations totaling approximately CNY4 billion in debt securities, which is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-24
Item 1.01
The Company entered into an engagement letter with counsel to facilitate an uplisting from OTC Markets to NASDAQ and a contemplated bridge financing. While the engagement itself is a material contract supporting significant corporate transactions (uplisting and bridge financing), the 8-K Item 1.01 disclosure focuses on the legal services engagement rather than the uplisting or financing transactions themselves. The uplisting and bridge financing are contemplated but not yet executed, making this primarily an operational/strategic milestone (engagement of counsel for major transactions) rather than a completed M&A activity or debt issuance.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-24
Item 5.03
The filing discloses multiple governance amendments: a corporate name change from "Hawkeye Systems, Inc." to "Hawkeye Digital, Inc.," a substantial increase in authorized shares from 450 million to 10.05 billion shares, and implementation of a classified board structure. While Item 5.03 typically covers routine bylaw amendments, the magnitude of the authorized share increase (22x expansion) and the strategic rebrand signal a material governance restructuring that would affect investor assessment of the company's capital structure and strategic direction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-24
Item 1.01
Tianci Group entered into a material equipment procurement agreement with McQueen Tech for US$500,000 in cryptocurrency mining equipment (Model S21 XP by Bitmain) and related advisory services. The agreement represents a material strategic entry into the cryptocurrency mining business to support the company's mining trade operations. While this is a material definitive agreement under Item 1.01, it does not constitute M&A activity (no acquisition, merger, or change of control), debt issuance, or other specifically-named event types; it is a material operational/strategic business commitment that warrants disclosure as an operational event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
The filing discloses multiple unregistered sales of equity securities by Brookfield Real Estate Income Trust Inc. during August 2026, including 115,918 Class I shares to the Adviser as management fees, 24,886 Class C shares to a feeder vehicle, 6,517 Class I shares via distribution reinvestment to a feeder vehicle, 124,331 Class I shares via distribution reinvestment to Brookfield affiliates, and 26,633 Class E shares to Brookfield employees, totaling approximately $3.3 million in aggregate consideration. These private placements under Section 4(a)(2) and Regulation S/D represent dilutive equity issuances that would materially affect investor assessment of share ownership and capital structure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-24
Item 5.02
The Compensation Committee revised CEO Joseph Visconti's base salary to $250,000 and established a $150,000 performance bonus contingent on successful closing of a merger with USFM Corporation. This is a direct disclosure of compensatory arrangements for a named executive officer under Item 5.02(e), making it an exec_compensation event. The material nature is reinforced by the merger-contingent bonus structure and the CEO's central role in the transaction.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-24
EX-99.1
First Phosphate filed an updated NI 43-101 Technical Report on the Bégin-Lamarche Phosphate Project (effective May 1, 2026) showing a 378% increase in Indicated Mineral Resources compared to the prior September 2024 estimate. The report presents updated mineral resource estimates, drilling results from 2023–2026, metallurgical testwork, and a preliminary economic assessment, representing a material operational and strategic milestone for the company's flagship phosphate project.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-24
Item 8.01
Curaleaf's press release discloses an active acquisition offer for Aurora Cannabis, including detailed discussion of the offer terms, strategic rationale, and engagement status. The filing explicitly references "Curaleaf's offer for Aurora" and states "Curaleaf remains ready to engage constructively at any time" to discuss a deal. This constitutes material M&A activity under Item 8.01 (Other Events), as the company is publicly disclosing an ongoing acquisition proposal and its willingness to negotiate, which would materially affect investor assessment of both companies' strategic direction and shareholder value.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-24
Item 5.02
Mr. Dharmendra Kumar Sinha, President of Public Cloud, is departing effective September 14, 2026. The disclosure centers on the departure itself—the principal action is a named executive leaving his position. While a separation agreement is mentioned, the core event is the departure, not compensation arrangements. This is material as it involves a senior officer departure at a public company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Blue Owl Credit Income Corp. completed an unregistered private placement of 251,525 shares of Class I common stock to feeder vehicles for approximately $2.3 million, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-24
Item 8.01
The board declared monthly distributions to shareholders across Class S, D, and I shares at $0.070100 per share gross, payable in September, October, and November 2026.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-24
Item 5.02
Jim McGinty resigned from the Board of Directors of BARK, Inc., effective August 21, 2026. The disclosure centers on the departure of a director and the resulting reduction in board size from eight to seven members. While the filing notes no disagreement with management or policies, the resignation of a board member is a material governance event affecting the composition of the company's leadership structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-24
EX-99.1
This press release announces achievement of a research milestone in a strategic collaboration between VERAXA and Secarna Pharmaceuticals to develop antibody-oligonucleotide conjugates (AOCs). The disclosure describes successful in vitro proof-of-concept results demonstrating the potential of combining both parties' technologies. While this is a partnership milestone rather than a discrete M&A transaction, it represents a material operational/strategic development in VERAXA's pipeline advancement and technology validation that would be relevant to investors assessing the company's progress and competitive positioning in next-generation therapeutics.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-24
Item 8.01
This disclosure centers on a series of material court orders in multiple related pipeline litigation cases involving Sable Offshore Corp. The Company faces a $1.449 million penalty for violating a consent decree, declaratory judgments affecting its pipeline operations, and ongoing legal challenges to its restart of the Santa Ynez Pipeline System. These outcomes directly impact the Company's ability to operate its core business asset and represent material litigation developments that would affect a reasonable investor's assessment of the registrant's legal and operational risks.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Blue Owl Technology Income Corp. completed an unregistered private placement of 136,101 shares of Class I common stock to feeder vehicles for $1,316,100, exempt under Section 4(a)(2) and Regulation S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-24
Item 8.01
The board declared monthly distributions payable in September, October, and November 2026 to shareholders of record, with per-share amounts of $0.067794 for Class S, $0.072722 for Class D, and $0.074775 for Class I (net distributions).
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-24
EX-99.1
Gogoro released its second quarter 2026 financial results, reporting revenue of $70.6 million, a net loss of $4.9 million (improved from $26.5 million year-over-year), gross margin of 22.6%, and adjusted EBITDA of $19.3 million, along with updated 2026 guidance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-08-24
EX-99.2
Gogoro appointed Jacky Lee as Principal Financial Officer effective August 21, 2026, succeeding CFO Bruce Aitken who is retiring effective September 1, 2026. Lee brings relevant financial and operational experience to the role.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-24
Item 6.04
The filing discloses a distribution overpayment to certificateholders totaling approximately $2.43 million due to a reduction in a curtailment payment on an underlying mortgage loan. While Item 6.04 addresses "Failure to Make a Required Distribution," the actual event here is not a failure to distribute but rather an erroneous overpayment that must be recovered. This is a financial accounting/distribution matter material to investors in the RMBS trust, but does not fit the specific categories of debt issuance, dividend distribution, or other named financial events—making it a financial_other event.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-24
Item 5.03
BRC Inc. filed Certificates of Amendment to its Charter to effect 1-for-10 reverse stock splits of both Class A and Class B common stock, effective August 21, 2026. This amendment to the articles of incorporation materially affects the share count, trading price, and proportionate ownership of all shareholders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-24
Item 1.01
Expion360 acquired oil and gas exploration assets in Eastern Louisiana for an adjusted purchase price of $3,425,000 in cash, including leasehold, wellbore, mineral title research, and intellectual property. The acquisition marks the company's entry into the oil and gas sector and is accompanied by a strategic exploration agreement committing up to $4 million in financing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-24
Item 5.02
Kevin Sellers was appointed as Chief Executive Officer and Board member effective August 24, 2026, following Joseph Hammer's resignation from the CEO role. Sellers' appointment includes an employment agreement with base salary, bonus, and RSU grant as the company undergoes strategic expansion into oil and gas.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-24
Item 7.01
Golub Capital Private Credit Fund declared and disclosed payment details for regular monthly distributions to shareholders of Class I and Class S shares, with distribution amounts of $0.1875 per Class I share and $0.1704 net per Class S share, record date of August 31, 2026, and payment date on or around September 29, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-08-24
Item 7.01
The filing discloses Golub Capital Private Credit Fund's quarterly update for Q2 2026, including NAV per share ($24.17), quarterly returns (2.47% for Class I), year-to-date performance (0.62%), portfolio composition ($9.6 billion in total investments), and detailed performance metrics and credit health indicators. This is a periodic financial results disclosure typical of closed-end funds, analogous to an earnings release, furnished under Item 7.01 (Regulation FD Disclosures) with the quarterly update attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-24
The filing's primary disclosure under Item 8.01 is the Board's declaration of cash distributions on all share classes (Class FA, A, T, D, I, and S) with a record date of September 25, 2026 and payment date of September 28, 2026. While the filing also includes NAV determinations and public offering price adjustments, the central material event is the distribution declaration, which is a routine but material disclosure for a closed-end fund. The distribution amounts per share are explicitly stated for each class.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
The filing discloses an unregistered sale of 272,642 common shares for $7,126,860 pursuant to Section 4(a)(2) and Regulation D/S under the Securities Act. This is a classic dilutive issuance of equity securities outside registered offerings, which materially affects existing shareholders' ownership percentages and is a key disclosure for investors assessing capital structure and dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Golub Capital Private Income Fund S issued 2,068 common shares of beneficial interest for $50,000 in consideration pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions, representing an unregistered equity issuance outside registered offerings.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-24
Item 7.01
The fund declared a regular distribution to Common Shareholders of $0.1492 per share (net of fees), with a record date of August 31, 2026 and payment date on or around September 29, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-24
Item 3.02
Golub Capital Private Income Fund I issued 53,881 common shares of beneficial interest for $1,305,000 as of August 1, 2026, pursuant to subscription agreements and exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-24
Item 7.01
The fund declared a regular distribution of $0.1667 per Common Share on July 31, 2026, payable to shareholders of record as of August 31, 2026, with payment on or around September 29, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-08-24
Item 8.01
The fund disclosed portfolio composition, net asset value, and leverage metrics as of July 31, 2026, providing investors with current information on the fund's asset composition and financial position.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-24
EX-99.1
The exhibit announces the appointments of Desmond Tranquilla as Chief Projects Officer and Ruben Wallin as Senior Vice President, Sustainability—two senior executive positions at a development-stage gold company advancing toward a construction decision in 2028. The CEO explicitly states these appointments "strengthen two critical areas of project execution on an accelerated timeline," and both appointees bring 30+ years of relevant mining and permitting experience. The announcement also discloses equity grants (stock options and PRSUs) tied to these roles, which are compensatory arrangements incidental to the appointments themselves.
View raw filing on EDGAR →